NYSEAMERICAN:PFNX - Pfenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.20 +0.12 (+2.94 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$4.08
Today's Range$4.08 - $4.26
52-Week Range$3.13 - $8.42
Volume60,400 shs
Average Volume53,022 shs
Market Capitalization$132.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees65
Market Cap$132.14 million
Next Earnings Date3/21/2019 (Estimated)
OptionableOptionable

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) released its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05. The biotechnology company had revenue of $4.19 million for the quarter, compared to analysts' expectations of $5.55 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

2 brokerages have issued twelve-month price targets for Pfenex's stock. Their predictions range from $8.00 to $8.00. On average, they anticipate Pfenex's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

News headlines about PFNX stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfenex earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

Are investors shorting Pfenex?

Pfenex saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 690,959 shares, an increase of 2.0% from the January 15th total of 677,726 shares. Based on an average daily trading volume, of 46,504 shares, the short-interest ratio is presently 14.9 days. Approximately 2.2% of the shares of the company are short sold. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Relypsa (RLYP), Verastem (VSTM), Incyte (INCY), Spectrum Pharmaceuticals (SPPI), Fate Therapeutics (FATE), Repros Therapeutics (RPRX), Novo Nordisk A/S (NVO), Rigel Pharmaceuticals (RIGL), Omeros (OMER) and Exelixis (EXEL).

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.16%), Sanders Morris Harris LLC (2.48%), Dimensional Fund Advisors LP (2.15%), Northern Trust Corp (1.04%), Geode Capital Management LLC (0.96%) and Two Sigma Investments LP (0.33%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Jason Grenfell-Gardner, Patricia Lady, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Two Sigma Investments LP, Two Sigma Advisers LP and Algert Global LLC. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Dimensional Fund Advisors LP, Virtu Financial LLC, Bank of New York Mellon Corp, Rhumbline Advisers, Squarepoint Ops LLC and Geode Capital Management LLC. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Jason Grenfell-Gardner, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $4.20.

How big of a company is Pfenex?

Pfenex has a market capitalization of $132.14 million. Pfenex employs 65 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel